Editor's note: Seeking Alpha is proud to welcome Alexander Madjarov as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.My name is Alexander Madjarov I have a bachelors degree in business and management from AUBG. Although I have began investing with my own capital 2 years ago, I have been building my stock market expertise for the last 5 years. During th ...

-Â Â EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) Â is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy -Â Â In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2 with approximately 3 out of 4 patients achieving a complete response -Â Â Approval marks third ...

Trip.com Group Ltd (NASDAQ:TCOM) is entering a new stage of growth, one driven less by post-recovery tailwinds and more by structural advantages taking hold across its global platform.Benchmark Equity Research analyst Fawne Jiang views the company as entering a more durable expansion cycle, which leads her to reaffirm a Buy rating and raise her price target to $82 from $80.She highlights resilient travel demand, accelerating international scale, and expanding operating leverage as the foundations of this sh ...

Shares of Ampco-Pittsburgh Corporation (AP) have surged 31.4% since the company released results for the quarter ended Sept. 30, 2025, sharply outperforming the S&P 500 Index’s 3.3% decline over the same period. Over the past month, the stock has gained 25.8%, whereas the S&P 500 lost 1.2%.AP’s Earnings SnapshotAmpco-Pittsburgh’s third-quarter 2025 results showed notable year-over-year improvement. Net sales rose 12.3% to $108 million from $96.2 million in the prior-year quarter, driven by higher shipment v ...

Key Takeaways The phase II study showed VTX3232 was safe and well-tolerated as monotherapy and with Wegovy.VTYX reported major hsCRP and IL-6 reductions plus improvements in key inflammatory biomarkers.Combination therapy with Wegovy cut inflammation further but did not enhance weight-loss outcomes.Shares of Ventyx Biosciences (VTYX) have skyrocketed 156% in the past month. The massive surge in the stock price was primarily driven by the success of the company’s mid-stage study evaluating its investigationa ...

Core Insights - Hims & Hers Health, Inc. (HIMS) has faced short-term stock losses, declining 15.6% over the past three months, underperforming the industry and broader market [1][10] - The company launched its in-depth testing experience, Labs, and announced its third-quarter 2025 results, showing strong revenue growth but disappointing bottom-line performance [2][3] Financial Performance - In Q3 2025, HIMS reported significant top-line improvement and subscriber growth, but experienced margin contraction, leading to weak earnings [3][10] - Revenue expectations for Q4 2025 are projected between $605 million and $625 million, reflecting a year-over-year increase of 26%-30%, while full-year revenues are expected to be between $2.335 billion and $2.355 billion, indicating growth of 58%-59% from 2024 [8] Competitive Landscape - HIMS has underperformed compared to peers like Teladoc Health, which lost 8%, but outperformed American Well Corporation, which saw a 44.2% decline [7] - The competitive environment is intensifying, with traditional healthcare providers and digital health platforms posing challenges for customer acquisition and retention [14] Operational Challenges - The company faces regulatory complexities as it expands into sterile compounding and laboratory testing, which involve stringent compliance requirements [11] - Uncertainty surrounding compounded GLP-1 medications could impact demand trends, particularly in weight-loss offerings [12] - Rapid expansion strains operational efficiency, requiring precise execution to maintain quality and customer experience [13] Growth Drivers - HIMS is expanding into high-value clinical categories, enhancing customer lifetime value and supporting revenue scaling through initiatives like Labs and offerings in menopause and hormone health [16] - The acquisition of ZAVA and planned international expansions position HIMS to replicate its U.S. care model in regions with unmet needs [17] Valuation Metrics - HIMS' forward 12-month price-to-sales (P/S) ratio is 2.9X, lower than the industry average of 5.1X but higher than its three-year median of 2.5X [18] - Compared to peers, Teladoc Health and Amwell have lower forward P/S ratios of 0.5X and 0.3X, respectively [20] Estimate Movements - Earnings estimates for HIMS have decreased by 20% to 48 cents over the past 60 days [21] - Recent estimate revisions indicate a significant downward trend in earnings expectations [22] Overall Assessment - HIMS shows strong core business strength and growth potential, but current market conditions suggest caution for investors despite favorable long-term prospects [24][25]

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric th ...

Amer Sports, Inc. (NYSE:AS) delivered a stronger-than-expected third quarter, powered by standout performance in its outdoor brands and tight cost control.Yet the upbeat results are tempered by recent brand headwinds in China and a cautious outlook that could determine the stock's next move.The company reported third-quarter adjusted earnings per share of 33 cents, beating the analyst consensus estimate of 25 cents.Also Read: Target Q3 Preview: Pressure From Walmart, Amazon And Tariffs Could Weigh On Result ...

Table of Contents Expand Table of Contents As Berkshire Hathaway's Warren Buffett passes the baton to his successor as CEO, his company is making surprising portfolio moves. Johannes Eisele / Getty Images Close Key Takeaways As Buffett prepares to step back as CEO of Berkshire Hathaway, the company is making moves few would expect from the Oracle of Omaha. Buffett spent decades telling investors he doesn't understand technology stocks well enough to bet big on them. Yet Berkshire Hathaway's latest Securitie ...

Group 1 - Snowflake (SNOW) is experiencing a strong performance, gaining 64% year to date, and is finding support at a key level near a buy point [1] - The stock is highlighted as a selection for IBD 50 Growth Stocks To Watch, indicating its potential for further profit [1] - Other companies like Alphabet and Nvidia also saw significant stock price increases, suggesting a positive trend in the tech sector [4] Group 2 - The article mentions that several stocks, including those in the AI sector, are nearing buy points, reflecting investor interest in growth opportunities [4] - There is a focus on the aerospace sector alongside Snowflake, indicating a diverse range of industries performing well [4] - The market is currently influenced by trade talks and CPI data, which could impact stock performance [4]